611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Roll Up Your Sleeve and Donate Blood for Cancer PatientsRadiation Treatment Is Hard on the HeartVaping Causes DNA Changes Similar to Those in Cancer: StudyFDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer RiskMore Sex Partners, Higher Cancer Risk?More Aggressive Surgery Can Extend Survival From Brain Cancer: StudyFor Patients on Blood Thinners, GI Bleeding May Signal Colon Cancer: StudyCRISPR Gene Editing Creates 'Designer' Immune Cells That Fight CancerHealth Risks Persist for Young Cancer SurvivorsNew Gene Study Unravels Cancer's SecretsWith Equal Access to Care, Blacks, Whites Have Similar Prostate Cancer OutcomesStrong Support Network Is Key to Women's Cancer Recovery: StudyCervical Cancer Could All But Disappear in North America by 2040New Study Supports Lowering Age of First ColonoscopyStudy Confirms CT Screenings Can Cut Lung Cancer DeathsToo Few Patients Enrolling in Cancer TrialsPsychedelic Drug Eases Cancer Patients' Distress Long TermImaging Technique Tracks Down Stray Lung Cancer Cells for SurgeonsColon Cancer Hits Poor, City Dwellers Hardest: StudyFaulty Immune System May Lead to Lung CancerEating More Veggies Won't Stop Prostate Cancer: StudyFor Cancer Survivors, Financial Hardship Is Common: SurveySunscreen Chemicals Absorbed Into Body, Study FindsHow Lack of Insurance Affects Breast Cancer SurvivalFewer Childhood Cancer Survivors Getting Hit by Heart TroublesAI Might Help Spot, Evaluate Prostate CancerSurgery May Add Years for Patients With Deadly Brain Cancer: StudyMore Than Half of Cancer Survivors Don't Abstain From AlcoholTargeted Ultrasound Destroys Cancer Without Harming Healthy Cells: Study'Less Is More' When it Comes to Testicular Cancer Chemo, Study SuggestsHealth Tip: Preparing for a Wig During Cancer TreatmentProgress Against Lung Cancer Fuels Record Drop in U.S. Cancer DeathsLarge Study Shows No Strong Link Between Baby Powder, Ovarian CancerAHA News: Statins May Do Double Duty on Heart Disease and CancerWeight-Loss Surgery Might Also Lower Skin Cancer RiskAI Beat Humans in Spotting Breast TumorsStomach Cancer Appears Different in Younger PatientsBreast Density Alerts Might Not Be Helping WomenYoung Cancer Patients Fare Better on Private InsuranceObesity May Boost Effectiveness of a Lung Cancer TherapyCould 1 Dose of HPV Vaccine Be Enough?Acupuncture May Ease a Common Side Effect of Cancer TreatmentHealth Tip: Breast Cancer Screening GuidelinesEnhertu Approved for Unresectable, Metastatic HER2+ Breast CancerYoung Colon Cancer Patients Have Fared Better Under ObamacareFDA Approves Padcev for Treatment of Advanced Urothelial CancerShe Never Smoked -- And Got Lung Cancer in Her 40sShedding Pounds May Shrink Breast Cancer RiskMost Long-Term Breast Cancer Survivors Die From Other CausesBreast Cancer Drug Shows Long-Lasting Prevention Power
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

HealthDay News
by -- E.J. Mundell
Updated: Feb 14th 2020

new article illustration

THURSDAY, Feb. 13, 2020 (HealthDay News) -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S. market.

Eisai Inc. has already "submitted a request to voluntarily withdraw the drug," Dr. Janet Woodcock, who directs the FDA's Center for Drug Evaluation and Research, noted in a statement issued Thursday.

Now, "we're taking steps to notify the public," she said, adding that "our review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment."

Woodcock said the FDA is advising that "patients should stop using the medication Belviq and Belviq XR [lorcaserin] and talk to their health care professionals about other treatment options for weight loss. Health care professionals should stop prescribing and dispensing Belviq and Belviq XR."

The agency first announced that Belviq might have links to cancer in a communication issued Jan 15.

At the time, the FDA said "we cannot conclude that lorcaserin contributes to the cancer risk," but "wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."

That review appears to have led to calls for the voluntary withdrawal of the medication.

Belviq increases feelings of fullness so that people eat less. It's available as a tablet (Belviq) and an extended-release tablet (Belviq XR).

According to the FDA, Belviq was first approved in 2012 as an add-on therapy to help aid weight loss, along with diet and exercise, in people who were obese or overweight.

Contingent on approval, the FDA ordered a randomized, placebo-controlled trial be conducted involving 12,000 people tracked for more than five years.

The trial wrapped up in June 2018, and the data showed that while 7.1% of those taking a "dummy" placebo developed cancer, that number rose to 7.7% among those taking Belviq.

"A range of cancer types was reported," the FDA said. "Several different types of cancers occurred more frequently among patients treated with Belviq, including pancreatic, colorectal and lung cancer. During the trial, one additional cancer per 470 patients treated with the medication for one year was observed."

People who have already taken Belviq should stop taking it, but "the FDA is not recommending special screening for patients who have taken Belviq," Woodcock said.

More information

There's more on maintaining a healthy weight at the American Heart Association.